Sleep Disorders Drug Development Pipeline Review, 2017

  • ID: 4410329
  • Report
  • Region: Global
  • 76 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Eisai Co Ltd
  • Galenica Ltd
  • Idorsia Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE

Summary

Restless legs syndrome is characterized by a distressing, irresistible need or urge to move the legs. There are a total of eight products in development for this indication, by eight companies. Key companies operating in this pipeline space include Mundipharma International and Galenica.

Nocturia describes the excessive urination at night. There are a total of eight products in development for this indication, by six companies. Key companies operating in this pipeline space include Ferring International and Sanwa Kagaku Kenkyusho.

Finally, Insomnia is a serious sleeping disorder characterized by the inability to fall or stay asleep. There are a total of 31 products in development for this indication, by 27 companies and three academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Merck and Overseas Pharmaceuticals.

Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

The report,"Sleep Disorders Drug Development Pipeline Review, 2017" provides an overview of the sleep disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for sleep disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Eisai Co Ltd
  • Galenica Ltd
  • Idorsia Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE

1 Table of Contents

2 Introduction
2.1 Sleep Disorders Report Coverage
2.2 Restless Legs Syndrome - Overview
2.3 Nocturia - Overview
2.4 Insomnia - Overview

3 Therapeutics Development
3.1 Restless Legs Syndrome
3.2 Nocturia
3.3 Insomnia

4 Therapeutics Assessment
4.1 Restless Legs Syndrome
4.2 Nocturia
4.3 Insomnia

5 Companies Involved in Therapeutics Development
5.1 Restless Legs Syndrome
5.2 Nocturia
5.3 Insomnia

6 Dormant Projects
6.1 Restless Legs Syndrome
6.2 Nocturia
6.3 Insomnia

7 Discontinued Products
7.1 Restless Legs Syndrome
7.2 Insomnia

8 Product Development Milestones
8.1 Restless Legs Syndrome
8.2 Nocturia
8.3 Insomnia

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Restless Legs Syndrome
Table 2: Number of Products under Development by Companies Restless Legs Syndrome
Table 3: Products under Development by Companies Restless Legs Syndrome
Table 4: Number of Products under Development for Nocturia
Table 5: Number of Products under Development by Companies Nocturia
Table 6: Products under Development by Companies Nocturia
Table 7: Number of Products under Development for Insomnia
Table 8: Number of Products under Development by Companies Insomnia
Table 9: Number of Products under Development by Universities/Institutes Insomnia
Table 10: Products under Development by Companies Insomnia
Table 11: Products under Development by Universities/Institutes Insomnia
Table 12: Number of Products by Stage and Target Restless Legs Syndrome
Table 13: Number of Products by Stage and Mechanism of Action Restless Legs Syndrome
Table 14: Number of Products by Stage and Route of Administration Restless Legs Syndrome
Table 15: Number of Products by Stage and Molecule Type Restless Legs Syndrome
Table 16: Number of Products by Stage and Target Nocturia
Table 17: Number of Products by Stage and Mechanism of Action Nocturia
Table 18: Number of Products by Stage and Route of Administration Nocturia
Table 19: Number of Products by Stage and Molecule Type Nocturia
Table 20: Number of Products by Stage and Target Insomnia
Table 21: Number of Products by Stage and Mechanism of Action Insomnia
Table 22: Number of Products by Stage and Route of Administration Insomnia
Table 23: Number of Products by Stage and Molecule Type Insomnia
Table 24: Restless Legs Syndrome - Pipeline by Galenica Ltd
Table 25: Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc
Table 26: Restless Legs Syndrome - Pipeline by Merz Pharma GmbH & Co KgaA
Table 27: Restless Legs Syndrome - Pipeline by Mundipharma International Ltd
Table 28: Restless Legs Syndrome - Pipeline by Omeros Corp
Table 29: Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc
Table 30: Nocturia - Pipeline by Astellas Pharma Inc
Table 31: Nocturia - Pipeline by Ferring International Center SA
Table 32: Nocturia - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd
Table 33: Nocturia - Pipeline by Vantia Therapeutics
Table 34: Insomnia - Pipeline by Alexza Pharmaceuticals Inc
Table 35: Insomnia - Pipeline by Athenex Inc
Table 36: Insomnia - Pipeline by Eisai Co Ltd
Table 37: Insomnia - Pipeline by Evotec AG
Table 38: Insomnia - Pipeline by Grupo Ferrer Internacional SA
Table 39: Insomnia - Pipeline by Heptares Therapeutics Ltd
Table 40: Insomnia - Pipeline by Idorsia Ltd
Table 41: Insomnia - Pipeline by Intec Pharma Ltd
Table 42: Insomnia - Pipeline by Intra-Cellular Therapies Inc
Table 43: Insomnia - Pipeline by Johnson & Johnson
Table 44: Insomnia - Pipeline by Leading BioSciences Inc
Table 45: Insomnia - Pipeline by Merck & Co Inc
Table 46: Insomnia - Pipeline by Neurim Pharmaceuticals Ltd
Table 47: Insomnia - Pipeline by Reviva Pharmaceuticals Inc
Table 48: Insomnia - Pipeline by Shionogi & Co Ltd
Table 49: Insomnia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd
Table 50: Insomnia - Pipeline by Yangtze River Pharmaceutical Group
Table 51: Restless Legs Syndrome - Dormant Projects
Table 52: Nocturia - Dormant Projects
Table 53: Insomnia - Dormant Projects
Table 54: Restless Legs Syndrome - Discontinued Products
Table 55: Insomnia - Discontinued Products

List of Figures
Figure 1: Number of Products under Development for Restless Legs Syndrome
Figure 2: Number of Products under Development by Companies Restless Legs Syndrome
Figure 3: Number of Products under Development for Nocturia
Figure 4: Number of Products under Development by Companies Nocturia
Figure 5: Number of Products under Development for Insomnia
Figure 6: Number of Products under Development by Companies Insomnia
Figure 7: Number of Products under Development by Universities/Institutes Insomnia
Figure 8: Number of Products by Targets Restless Legs Syndrome
Figure 9: Number of Products by Stage and Targets Restless Legs Syndrome
Figure 10: Number of Products by Mechanism of Actions Restless Legs Syndrome
Figure 11: Number of Products by Stage and Mechanism of Actions Restless Legs Syndrome
Figure 12: Number of Products by Routes of Administration Restless Legs Syndrome
Figure 13: Number of Products by Stage and Routes of Administration Restless Legs Syndrome
Figure 14: Number of Products by Molecule Types Restless Legs Syndrome
Figure 15: Number of Products by Stage and Molecule Types Restless Legs Syndrome
Figure 16: Number of Products by Targets Nocturia
Figure 17: Number of Products by Stage and Targets Nocturia
Figure 18: Number of Products by Mechanism of Actions Nocturia
Figure 19: Number of Products by Stage and Mechanism of Actions Nocturia
Figure 20: Number of Products by Routes of Administration Nocturia
Figure 21: Number of Products by Stage and Routes of Administration Nocturia
Figure 22: Number of Products by Molecule Types Nocturia
Figure 23: Number of Products by Stage and Molecule Types Nocturia
Figure 24: Number of Products by Top 10 Targets Insomnia
Figure 25: Number of Products by Stage and Top 10 Targets Insomnia
Figure 26: Number of Products by Top 10 Mechanism of Actions Insomnia
Figure 27: Number of Products by Stage and Top 10 Mechanism of Actions Insomnia
Figure 28: Number of Products by Routes of Administration Insomnia
Figure 29: Number of Products by Stage and Routes of Administration Insomnia
Figure 30: Number of Products by Stage and Molecule Types Insomnia

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexza Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Athenex Inc
  • Eisai Co Ltd
  • Evotec AG
  • Ferring International Center SA
  • Galenica Ltd
  • Grupo Ferrer Internacional SA
  • Heptares Therapeutics Ltd
  • Hisamitsu Pharmaceutical Co Inc
  • Idorsia Ltd
  • Intec Pharma Ltd
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • Leading BioSciences Inc
  • Merck & Co Inc
  • Merz Pharma GmbH & Co KgaA
  • Mundipharma International Ltd
  • Neurim Pharmaceuticals Ltd
  • Omeros Corp
  • Reviva Pharmaceuticals Inc
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Serina Therapeutics Inc
  • Shionogi & Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Vantia Therapeutics
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll